SNNAQ — Sienna Biopharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Sienna Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2015 December 31st	2016 December 31st	2017 December 31st	2018 December 31st
Period Length:	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	10-K	10-K
Standards:	USG	USG	USG	USG
Status:	Final	Final	Final	Final
Total Revenue	0	0	0	0
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	11.1	20.7	48.6	76.5
Operating Profit	-11.1	-20.7	-48.6	-76.5
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-11.3	-21.2	-50.8	-73.5
Provision for Income Taxes
Net Income After Taxes	-11.3	-21.2	-41.6	-73.5
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-11.3	-21.2	-50.5	-73.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-11.3	-21.2	-50.5	-73.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.568	-0.98	-2.01	-3.59
Dividends per Share